Archive for March, 2013

NEW YORK (AP) A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday.

It's the latest mega-collaboration to learn more about the intricate mechanisms that lead to cancer. And while the headway seems significant in many ways, the potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.

And perhaps farther in the future these genetic clues might lead to new treatments.

"This adds another piece to the puzzle," said Harpal Kumar, chief executive of Cancer Research U.K., the charity which funded much of the research.

One analysis suggests that among men whose family history gives them roughly a 20 percent lifetime risk for prostate cancer, such genetic markers could identify those whose real risk is 60 percent.

The markers also could make a difference for women with BRCA gene mutations, which puts them at high risk for breast cancer. Researchers may be able to separate those whose lifetime risk exceeds 80 percent from women whose risk is about 20 to 50 percent. One doctor said that might mean some women would choose to monitor for cancer rather than taking the drastic step of having healthy breasts removed.

Scientists have found risk markers for the three diseases before, but the new trove doubles the known list, said one author, Douglas Easton of Cambridge University. The discoveries also reveal clues about the biological underpinnings of these cancers, which may pay off someday in better therapies, he said.

Experts not connected with the work said it was encouraging but that more research is needed to see how useful it would be for guiding patient care. One suggested that using a gene test along with PSA testing and other factors might help determine which men have enough risk of a life-threatening prostate cancer that they should get a biopsy. Many prostate cancers found early are slow-growing and won't be fatal, but there is no way to differentiate and many men have surgery they may not need.

Easton said the prospects for a genetic test are greater for prostate and breast cancer than ovarian cancer.

Breast cancer is the most common malignancy among women worldwide, with more than 1 million new cases a year. Prostate cancer is the second most common cancer in men after lung cancer, with about 900,000 new cases every year. Ovarian cancer accounts for about 4 percent of all cancers diagnosed in women, causing about 225,000 cases worldwide.

Link:
Scientists find new gene markers for cancer risk

By Ben Hirschler

LONDON (Reuters) - New research has nearly doubled the number of genetic variations implicated in breast, prostate and ovarian cancer, offering fresh avenues for screening at-risk patients and, potentially, developing better drugs.

The bumper haul of 74 gene changes that can increase risks for the three hormone-related cancers, announced by scientists on Wednesday, is the result of the largest ever study of its kind.

It follows an international project to analyze the DNA of more than 200,000 people - half of them with cancer and half from the general population - to find alterations that are more common in individuals with the disease.

Although each gene variation increases cancer risk by only a small amount, scientists calculate that the 1 percent of men carrying lots of the alterations could have a 50 percent increased risk of developing prostate cancer.

Women with multiple variants could see their risk of breast cancer increase by 30 percent.

Doug Easton of the University of Cambridge, one of the cancer researchers who led the work, said the batch of new genetic discoveries meant medical experts would be able to develop new cancer screening programs.

This will take time, since more research is needed to develop diagnostic tools.

"I would think that within five to 10 years this might be being used commonly, if not in a very widespread population base," said Paul Pharoah, also of the University of Cambridge.

Initially, the additional screening is likely to be targeted at patients with established cancer risk factors, such as carriers of BRCA gene faults. Women with BRCA faults are known to be at greater risk of developing breast and ovarian cancer.

Read more:
Record gene haul points to better cancer screening

Nephilim History part3
The truth about the demon host.

By: shieldoftheson

Read more:
Nephilim History part3 - Video

Gene modification
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Genet...

By: Suman Bhattacharjee

More here:
Gene modification - Video

Public release date: 27-Mar-2013 [ | E-mail | Share ]

Contact: Jordi Morato comunicacio@idibell.cat IDIBELL-Bellvitge Biomedical Research Institute

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells. These cells, administered intravenously, have the ability to go directly to the damaged lungs, acting as a "smart drug".

To enhance the effect, researchers have modified this cells by genetic engineering. The studies have been developed by a team led by Josep Maria Aran, researcher at the Human Molecular Genetics group of IDIBELL, in collaboration with researchers of the Pneumology group at Vall d'Hebron Research Institute (VHIR) and the Biomedical Research Network Centre for Respiratory Diseases (CIBERES). The outcomes of the research have supposed an international patent application managed by the Technology Transfer Office (TTO) at IDIBELL.

The researchers use adult mesenchymal stem cells extracted from adipose tissue obtained from liposuction. These cells are capable of enhancing the regeneration of the damaged lung tissue and secrete inflammatory proteins therein when injected into the blood.

Improvements

The novelty patented by IDIBELL and VHIR researchers has been the insertion of improvements through genetic engineering that can significantly enhance the anti-inflammatory and regenerative power of the mesenchymal cells. Specifically, researchers have modified the antagonist to secrete interleukin 33, a regulatory protein (cytokine) that has a fundamental role in the inflammatory process.

The treatment has proven to be very effective given intravenously, although it could be considered the option of administering it by inhalation.

In the administered dose, these stem cells do not involve immune rejection, because the body removes them after their function is performed. This makes them particularly useful for treating acute diseases.

Good results

Read more:
IDIBELL licenses Histocell, a patent for acute respiratory diseases with stem cells

SHANGHAI, March 27, 2013 /PRNewswire/ --Life Technologies Corporation (LIFE) today announced that its Applied Biosystems 3500xL Dx Genetic Analyzer has been approved by China's State Food and Drug Administration (SFDA) for clinical diagnostic use in China and the launch of 10 Assays from its joint venture with Daan Gene. The development marks a major extension of Life Technologies' capabilities to serve the clinical end market in China with Sanger-based solutions.

The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer designed for a wide range of sequencing applications. It delivers high quality performance, higher throughput and increased productivity for clinical laboratories around the world.

Together with Life Technologies' genetic analyzer 3500 Dx that was approved by SFDA for IVD use in 2011 in China, the 3500 series genetic analyzers are intended for use in a wide range of applications in the process of clinical research, including de novo sequencing and mutational profiling as well as HLA typing. The newly expanded offering of both the 3500 Dx and the 3500xL Dx provides hospitals of all sizes the flexibility they need to meet their unique throughput demands.

Based on the 3500 Dx series platform, ten assays have been developed or licensed by Guangzhou Life Technologies DaAn Diagnostics Co. Ltd, a joint venture that established in 2012 between Life Technologies and Daan Gene Co. Ltd. of Sun Yat Sen University. These assays will be used for genotypic and drug resistance testing, cancer mutation identification and the prenatal chromosome disorder detection. Currently, nine out of the ten assays are Research Use Only kits and the other one that can be used in Trisomy 21 prenatal screening for Down syndrome is SFDA registered. The company is currently conducting clinical trials and is actively seeking the SFDA approval for the remaining nine kits.

"The current approval of the 3500xL Dx by SFDA emphasizes Life Technologies' success in pursuing regulatory pathways for our diagnostics laboratory instruments as well as our vision to becoming a global leader in the molecular diagnostics industry," said Ronnie Andrews, president of Medical Sciences at Life Technologies.

"As in other countries, China is facing the challenges of fighting with infectious diseases like HBV, TB, HCV and HIV, as well as various genetic-based diseases like lung cancer, breast cancer, and ovarian cancers, etc. The early detection and treatment of these diseases will greatly increase the recovery and survival rate of patients," said Dr. Siddhartha Kadia, president of Life Technologies Greater China. "Life Technologies is committed to bring more medical diagnostic products, like the 3500xL Dx genetic analyzer to support clinical research and diagnostics, which are expected to lead to a higher quality of life for Chinese people and more economical healthcare solutions."

Applied Biosystems Sanger Sequencers supplied the technology that powered the Human Genome Project, and Sanger instruments remain the sequencing "gold-standard" for accuracy, reliability and ease of use. The participation of the sequencing technologies in clinical diagnostics is reshaping the disease treatment paradigm worldwide.

Additional products offered by Life Technologies for the molecular diagnostics lab market in China include: the Applied Biosystem 7500, 7500 Fast Dx, StepOne, StepOne Plus, ViiA7 Dx qPCR series. Veriti Dx Thermal Cycler is in the process of SFDA registration in China.

About Life Technologies Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21stcentury forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made byLife Technologies with the Securities and Exchange Commission.Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

See the original post:
Life Technologies Announces SFDA Clearance for its 3500xL Dx Genetic Analyzer in China and the Launch of 10 Assays ...

NEW YORK (AP) A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday.

It's the latest mega-collaboration to learn more about the intricate mechanisms that lead to cancer. And while the headway seems significant in many ways, the potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.

And perhaps farther in the future these genetic clues might lead to new treatments.

"This adds another piece to the puzzle," said Harpal Kumar, chief executive of Cancer Research U.K., the charity which funded much of the research.

One analysis suggests that among men whose family history gives them roughly a 20 percent lifetime risk for prostate cancer, such genetic markers could identify those whose real risk is 60 percent.

The markers also could make a difference for women with BRCA gene mutations, which puts them at high risk for breast cancer. Researchers may be able to separate those whose lifetime risk exceeds 80 percent from women whose risk is about 20 to 50 percent. One doctor said that might mean some women would choose to monitor for cancer rather than taking the drastic step of having healthy breasts removed.

Scientists have found risk markers for the three diseases before, but the new trove doubles the known list, said one author, Douglas Easton of Cambridge University. The discoveries also reveal clues about the biological underpinnings of these cancers, which may pay off someday in better therapies, he said.

Experts not connected with the work said it was encouraging but that more research is needed to see how useful it would be for guiding patient care. One suggested that using a gene test along with PSA testing and other factors might help determine which men have enough risk of a life-threatening prostate cancer that they should get a biopsy. Many prostate cancers found early are slow-growing and won't be fatal, but there is no way to differentiate and many men have surgery they may not need.

Easton said the prospects for a genetic test are greater for prostate and breast cancer than ovarian cancer.

Breast cancer is the most common malignancy among women worldwide, with more than 1 million new cases a year. Prostate cancer is the second most common cancer in men after lung cancer, with about 900,000 new cases every year. Ovarian cancer accounts for about 4 percent of all cancers diagnosed in women, causing about 225,000 cases worldwide.

Read the original:
Scientists find new genetic markers for cancer

NEW YORK, N.Y. - A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday.

It's the latest mega-collaboration to learn more about the intricate mechanisms that lead to cancer. And while the headway seems significant in many ways, the potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.

And perhaps farther in the future these genetic clues might lead to new treatments.

"This adds another piece to the puzzle," said Harpal Kumar, chief executive of Cancer Research U.K., the charity which funded much of the research.

One analysis suggests that among men whose family history gives them roughly a 20 per cent lifetime risk for prostate cancer, such genetic markers could identify those whose real risk is 60 per cent.

The markers also could make a difference for women with BRCA gene mutations, which puts them at high risk for breast cancer. Researchers may be able to separate those whose lifetime risk exceeds 80 per cent from women whose risk is about 20 to 50 per cent. One doctor said that might mean some women would choose to monitor for cancer rather than taking the drastic step of having healthy breasts removed.

Scientists have found risk markers for the three diseases before, but the new trove doubles the known list, said one author, Douglas Easton of Cambridge University. The discoveries also reveal clues about the biological underpinnings of these cancers, which may pay off someday in better therapies, he said.

Experts not connected with the work said it was encouraging but that more research is needed to see how useful it would be for guiding patient care. One suggested that using a gene test along with PSA testing and other factors might help determine which men have enough risk of a life-threatening prostate cancer that they should get a biopsy. Many prostate cancers found early are slow-growing and won't be fatal, but there is no way to differentiate and many men have surgery they may not need.

Easton said the prospects for a genetic test are greater for prostate and breast cancer than ovarian cancer.

Breast cancer is the most common malignancy among women worldwide, with more than 1 million new cases a year. Prostate cancer is the second most common cancer in men after lung cancer, with about 900,000 new cases every year. Ovarian cancer accounts for about 4 per cent of all cancers diagnosed in women, causing about 225,000 cases worldwide.

The rest is here:
Scientists ID genetic markers tied to breast, prostate, ovarian cancer; no quick payoff seen

NEW YORK A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday.

It's the latest mega-collaboration to learn more about the intricate mechanisms that lead to cancer. And while the headway seems significant in many ways, the potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.

And perhaps farther in the future these genetic clues might lead to new treatments.

"This adds another piece to the puzzle," said Harpal Kumar, chief executive of Cancer Research U.K., the charity which funded much of the research.

One analysis suggests that among men whose family history gives them roughly a 20 percent lifetime risk for prostate cancer, such genetic markers could identify those whose real risk is 60 percent.

The markers also could make a difference for women with BRCA gene mutations, which puts them at high risk for breast cancer. Researchers may be able to separate those whose lifetime risk exceeds 80 percent from women whose risk is about 20 to 50 percent. One doctor said that might mean some women would choose to monitor for cancer rather than taking the drastic step of having healthy breasts removed.

Scientists have found risk markers for the three diseases before, but the new trove doubles the known list, said one author, Douglas Easton of Cambridge University. The discoveries also reveal clues about the biological underpinnings of these cancers, which may pay off someday in better therapies, he said.

Experts not connected with the work said it was encouraging but that more research is needed to see how useful it would be for guiding patient care. One suggested that using a gene test along with PSA testing and other factors might help determine which men have enough risk of a life-threatening prostate cancer that they should get a biopsy. Many prostate cancers found early are slow-growing and won't be fatal, but there is no way to differentiate and many men have surgery they may not need.

Easton said the prospects for a genetic test are greater for prostate and breast cancer than ovarian cancer.

Breast cancer is the most common malignancy among women worldwide, with more than 1 million new cases a year. Prostate cancer is the second most common cancer in men after lung cancer, with about 900,000 new cases every year. Ovarian cancer accounts for about 4 percent of all cancers diagnosed in women, causing about 225,000 cases worldwide.

See more here:
Genetic Markers For Cancer Risk Identified In Huge International Effort

Mar. 27, 2013 An international research collaboration has found five new regions of the human genome that are linked to increased risks for developing ovarian cancer. Duke Medicine researchers played a leading role analyzing genetic information from more than 40,000 women.

The findings are published in four studies, two appearing in the journal Nature Communications and two in Nature Genetics on March 27, 2013. The research is being published as part of a coordinated release of new data from the Collaborative Oncological Gene-environment Study (COGS), an international effort to identify genetic variations that make certain people susceptible to developing breast, prostate and ovarian cancers.

According to the National Cancer Institute, ovarian cancer accounts for 3 percent of all cancers in women and is the leading cause of death among cancers of the female reproductive system. This is due to the lack of early symptoms or effective screening tests.

Inherited mutations in the BRCA1 and BRCA2 genes dramatically increase ovarian cancer risk. Genetic testing for BRCA1 and BRCA2 mutations can identify women who would benefit most from surgery to prevent ovarian cancer, but this is relevant to less than 1 percent of the population. Other genetic variants that are more common may also affect ovarian risk. The Ovarian Cancer Association Consortium previously described six such genetic differences and now the COGS project has found five more.

"Because ovarian cancer is relatively uncommon, it is critically important to identify subsets of women at increased risk," said senior coauthor Andrew Berchuck, MD, director of the division of gynecologic oncology at Duke Cancer Institute. "Although the common genetic risk variants for ovarian cancer discovered thus far are not strong enough to use in practice, this may become a reality as additional variants are discovered. This could facilitate development of ovarian cancer screening and prevention strategies directed towards women most likely to benefit."

"Our hope is that these genetic variants, along with established epidemiologic factors, such as reproductive history, will not only enhance our ability to predict which women are at increased risk for developing this highly fatal disease, but will also provide new insight into the underlying biology and pathogenesis of ovarian cancer," said epidemiologist Joellen Schildkraut, PhD, director of the Cancer Control and Population Sciences program at Duke Cancer Institute. She is a senior coauthor of one of the Nature studies and the principal investigator of the North Carolina Ovarian Cancer Study, one of the studies that contributed data to this discovery.

"Because of the large number of study subjects, we were able to determine that some genetic variants were important to specific subgroups of ovarian cancer, suggesting possible differences in the underlying cause of these subtypes," Schildkraut said.

Additional studies on the biology of these genetic variants could help researchers develop new tests to predict which women are at risk of developing ovarian cancer, and potentially lead to therapies that better treat the disease.

In addition to Berchuck and Schildkraut, Duke study authors include Rachel Palmieri Weber of the Department of Community and Family Medicine and Edwin Iversen of the Department of Statistical Science and Cancer Prevention, Detection and Control Research Program.

Share this story on Facebook, Twitter, and Google:

Read more from the original source:
Five genetic variations increase risk of ovarian cancer

By Duke Medicine News and Communications

DURHAM, N.C. -- An international research collaboration has found five new regions of the human genome that are linked to increased risks for developing ovarian cancer. Duke Medicine researchers played a leading role analyzing genetic information from more than 40,000 women.

The findings are published in four studies, two appearing in the journal Nature Communications and two in Nature Genetics on March 27, 2013. The research is being published as part of a coordinated release of new data from the Collaborative Oncological Gene-environment Study (COGS), an international effort to identify genetic variations that make certain people susceptible to developing breast, prostate and ovarian cancers.

According to the National Cancer Institute, ovarian cancer accounts for 3 percent of all cancers in women and is the leading cause of death among cancers of the female reproductive system. This is due to the lack of early symptoms or effective screening tests.

Inherited mutations in the BRCA1 and BRCA2 genes dramatically increase ovarian cancer risk. Genetic testing for BRCA1 and BRCA2 mutations can identify women who would benefit most from surgery to prevent ovarian cancer, but this is relevant to less than 1 percent of the population. Other genetic variants that are more common may also affect ovarian risk. The Ovarian Cancer Association Consortium previously described six such genetic differences and now the COGS project has found five more.

"Because ovarian cancer is relatively uncommon, it is critically important to identify subsets of women at increased risk," said senior coauthor Andrew Berchuck, MD, director of the division of gynecologic oncology at Duke Cancer Institute. "Although the common genetic risk variants for ovarian cancer discovered thus far are not strong enough to use in practice, this may become a reality as additional variants are discovered. This could facilitate development of ovarian cancer screening and prevention strategies directed towards women most likely to benefit."

"Our hope is that these genetic variants, along with established epidemiologic factors, such as reproductive history, will not only enhance our ability to predict which women are at increased risk for developing this highly fatal disease, but will also provide new insight into the underlying biology and pathogenesis of ovarian cancer," said epidemiologist Joellen Schildkraut, PhD, director of the Cancer Control and Population Sciences program at Duke Cancer Institute. She is a senior coauthor of one of the Nature studies and the principal investigator of the North Carolina Ovarian Cancer Study, one of the studies that contributed data to this discovery.

"Because of the large number of study subjects, we were able to determine that some genetic variants were important to specific subgroups of ovarian cancer, suggesting possible differences in the underlying cause of these subtypes," Schildkraut said.

Additional studies on the biology of these genetic variants could help researchers develop new tests to predict which women are at risk of developing ovarian cancer, and potentially lead to therapies that better treat the disease.

In addition to Berchuck and Schildkraut, Duke study authors include Rachel Palmieri Weber of the Department of Community and Family Medicine and Edwin Iversen of the Department of Statistical Science and Cancer Prevention, Detection and Control Research Program. A full list of researchers and their affiliations can be found in the manuscripts.

Read the rest here:
Five Genetic Variations Found to Increase Risk of Ovarian Cancer

Public release date: 27-Mar-2013 [ | E-mail | Share ]

Contact: Rachel Harrison rachel.harrison@duke.edu 919-419-5069 Duke University Medical Center

DURHAM, N.C. -- An international research collaboration has found five new regions of the human genome that are linked to increased risks for developing ovarian cancer. Duke Medicine researchers played a leading role analyzing genetic information from more than 40,000 women.

The findings are published in four studies, two appearing in the journal Nature Communications and two in Nature Genetics on March 27, 2013. The research is being published as part of a coordinated release of new data from the Collaborative Oncological Gene-environment Study (COGS), an international effort to identify genetic variations that make certain people susceptible to developing breast, prostate and ovarian cancers.

According to the National Cancer Institute, ovarian cancer accounts for 3 percent of all cancers in women and is the leading cause of death among cancers of the female reproductive system. This is due to the lack of early symptoms or effective screening tests.

Inherited mutations in the BRCA1 and BRCA2 genes dramatically increase ovarian cancer risk. Genetic testing for BRCA1 and BRCA2 mutations can identify women who would benefit most from surgery to prevent ovarian cancer, but this is relevant to less than 1 percent of the population. Other genetic variants that are more common may also affect ovarian risk. The Ovarian Cancer Association Consortium previously described six such genetic differences and now the COGS project has found five more.

"Because ovarian cancer is relatively uncommon, it is critically important to identify subsets of women at increased risk," said senior coauthor Andrew Berchuck, MD, director of the division of gynecologic oncology at Duke Cancer Institute. "Although the common genetic risk variants for ovarian cancer discovered thus far are not strong enough to use in practice, this may become a reality as additional variants are discovered. This could facilitate development of ovarian cancer screening and prevention strategies directed towards women most likely to benefit."

"Our hope is that these genetic variants, along with established epidemiologic factors, such as reproductive history, will not only enhance our ability to predict which women are at increased risk for developing this highly fatal disease, but will also provide new insight into the underlying biology and pathogenesis of ovarian cancer," said epidemiologist Joellen Schildkraut, PhD, director of the Cancer Control and Population Sciences program at Duke Cancer Institute. She is a senior coauthor of one of the Nature studies and the principal investigator of the North Carolina Ovarian Cancer Study, one of the studies that contributed data to this discovery.

"Because of the large number of study subjects, we were able to determine that some genetic variants were important to specific subgroups of ovarian cancer, suggesting possible differences in the underlying cause of these subtypes," Schildkraut said.

Additional studies on the biology of these genetic variants could help researchers develop new tests to predict which women are at risk of developing ovarian cancer, and potentially lead to therapies that better treat the disease.

Continue reading here:
5 genetic variations increase risk of ovarian cancer

use acceptance as surrender vlog voice daily logical personal thinking individual Psychology

By: cett daee

Read more:
use acceptance as surrender vlog voice daily logical personal thinking individual Psychology - Video

How To Breathe Into Your Balls Like A Boss
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

Originally posted here:
How To Breathe Into Your Balls Like A Boss - Video

Extraterrestes,camino hacia la Luz-Vol.037-Luz Genética.(1ª)Juan Marco
Las cadenas(genes) del pasado existen, atan la enseñanza planetaria,cuando aprendemos, liberan enseñanzas hacia el futuro. Mis libros GRATIS; http://www.juan...

By: Juan Marco

Read the original:
Extraterrestes,camino hacia la Luz-Vol.037-Luz Genética.(1ª)Juan Marco - Video

Extraterrestes,camino hacia la Luz-Vol.038-Luz Genética.(2ª)Juan Marco
La genética produce diferentes informaciones para su manifestación en la vida, una parte, biológica, otra psicosomática, la más importante; como podemos apre...

By: Juan Marco

Follow this link:
Extraterrestes,camino hacia la Luz-Vol.038-Luz Genética.(2ª)Juan Marco - Video

Gene cloning
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Molec...

By: Suman Bhattacharjee

Originally posted here:
Gene cloning - Video

369| Protective Style Files, a New Journey! v.1
WATCH IN HD! Please check here for answers to your question. Thank you. I love you for watching. Visit my website! http://KinkyCurlyCoilyMe.com Hey loves! #39;v...

By: BlakIzBeautyful

Read more here:
369| Protective Style Files, a New Journey! v.1 - Video

Season 5 - Episode 49 Fabricators and Genes
Now that Xycraft is out, I get to show you guys Fabricators! Meanwhile, I #39;m working with Genetics.... Keep up with my thread here: http://www.minecraftforum....

By: direwolf20

Here is the original post:
Season 5 - Episode 49 Fabricators and Genes - Video

La scienza narrata - Vicenza 7.02.2013 - Lezione prof. Edoardo Boncinelli
Lezione del Prof. Edoardo Boncinelli (genetista e docente universitario) Palazzo Cordellina 7.02.2013 Sono intervenuti i docenti: Dott. Giovanni Nucci e Prof...

By: Lascienzanarrata

Excerpt from:
La scienza narrata - Vicenza 7.02.2013 - Lezione prof. Edoardo Boncinelli - Video

Qu #39;est-ce que l #39;agroécologie? Bernard Chevassus-au-Louis en parle à Gembloux Agro-Bio Tech (ULg)
"Quelques principes d #39;agroécologie", c #39;est le thème de la conférence donnée par Bernard Chevassus-au-Louis à Gembloux Agro-Bio Tech le 22 mars 2013. Bernard ...

By: GemblouxAgroBioTech

View post:
Qu'est-ce que l'agroécologie? Bernard Chevassus-au-Louis en parle à Gembloux Agro-Bio Tech (ULg) - Video

I #39;m a Gym Virgin, What Should I Do?
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

Link:
I'm a Gym Virgin, What Should I Do? - Video

Newswise STONY BROOK, NY, March 26, 2013 The possible link between genetics and the development of autism will be the topic of the 17th Annual Swartz Foundation Mind/Brain Lecture at Stony Brook University on Monday, April 1, 2013 at 4:30 pm on the Main Stage of the Staller Center for the Arts. Guest lecturer Michael Wigler, Professor of Genetics at Cold Spring Harbor Laboratory and a trailblazer in the field of biomedical research, will present his findings on the connection.

The lecture, Considering the Genetics of Cognitive Function Through the Prism of Autism, is intended for a general audience and free and open to the public. The Mind/Brain Lecture Series is sponsored by Stony Brook University and its Department of Neurobiology and Behavior, and by The Swartz Foundation, which supports research at 11 centers for theoretical and computational neuroscience.

During the discussion, Professor Wigler will detail how genetics may be involved in the development of autism. The terms autism and autism spectrum disorders are used to describe a common developmental cognitive-behavioral disorder characterized by disabling defects in social response and communication, along with inappropriate repetitive behaviors. There is a strong male bias among those diagnosed, especially among the lesser affected. While the influence of the environment is a factor in causation, the involvement of genetics is clear.

The autism risk for a newborn is more than tenfold higher if a prior sibling has the disorder, and nearly 50 percent for a male newborn if two previous siblings have been affected. Professor Wigler will discuss the evidence that new mutations in the parental germline, especially the fathers, contributes to the disorder, and increases with parental age. He will present a unified model that seeks to explain sporadic and familial autism.

Professor Wiglers lab estimates from the mutation data that the number of target genes is on the order of hundreds, and they have identified several dozen likely gene targets, many of which may be linked to neuroplasticity, the process by which our brains adapt to change. Although a very significant advance, the genetics does not yet fully explain the observed incidence rate. Professor Wigler will discuss the reason why, what scientists may be missing and what his research may mean for future treatment of those with autism.

The Swartz Foundation is pleased to have Professor Wigler as the guest lecturer at the 2013 Mind/Brain Lecture, said Dr. Jerome Swartz, Chairman of The Swartz Foundation. Professor Wigler's work on autism, especially the effects of new mutations of the gene transfers on the newborn's neural systems, are an intriguing and potentially powerful insight into a growing and frightening disease epidemic. It is very likely that not only will this research provide important information on autism, but it may also give us further insights into the normal workings of our neurological structures.

Please arrive early as seating is limited. A reception with the speaker will immediately follow the talk. For more on the lecture and to watch a preview video of Professor Wigler discussing his genetic/autism research, visit http://www.stonybrook.edu/sb/mind.

###

About the Speaker Michael Wigler has been a trailblazer in the field of biomedical research, including human genetic disorders, population genetics and cancer genomics, and his contributions to the field of mammalian genetics have led to breakthroughs in the treatment of strokes, heart disease and cancer. Wiglers work on mammalian cell gene transfer is nothing short of groundbreaking with several major scientific discoveries occurring behind the walls of Cold Spring Harbor Laboratory, where he has been since 1979. Wigler remains on the forefront of molecular cancer research, unraveling the mysteries of the genetic mutations driving the evolution of cancer cells and those that underlie genetic diseases, such as autism, and discovering new disease-causing genes.

About The Swartz Foundation The Swartz Foundation was established by Jerry Swartz in 1994 to explore the application of mathematical physics, computer science and engineering principles to neurobiology, as a path to better understand the brain/mind relationship. The Foundation supports post-doc research in computational neuroscience at 11 universities and scientific institutions, through centers at Harvard University, Princeton University, Yale University, Columbia University, Cold Spring Harbor Laboratory, and UC San Diego, and in partnership with the Sloan Foundation at their five Centers for Theoretical Neurobiology at Salk Institute, Cal Tech, UC San Francisco, NYU/Courant and Brandeis University. Learn more at http://www.TheSwartzFoundation.org.

Read more:
Stony Brook University Mind/Brain Lecture: The Connection Between Genetics and Autism

SALT LAKE CITY, March 26, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct homologous recombination deficiency (HRD) testing on patients enrolled in PharmaMar's Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death. This partnership represents Myriad Genetics' first publicly announced commercial collaboration with its new HRD test.

"We are very pleased to collaborate with PharmaMar on their PM1183 development program with our new HRD test," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We believe HRD status is the most effective mechanism for assessing patient response to DNA-damaging drugs and look forward to working closely with PharmaMar on this exciting new companion diagnostic program."

Myriad's HRD test is able to detect when a tumor has lost the ability to repair DNA damage and would therefore be more susceptible to the DNA-damaging classes of drugs. The test directly measures the end result of the loss of the DNA repair function regardless of the genomic causation. The HRD test is effective at detecting the loss of function irrespective of whether the defects in the genes involved in the DNA repair mechanism were caused by hereditary germ line mutations or somatic mutations accumulated during the patient's life.

Myriad's HRD test has been shown to accurately predict drug response in both ovarian cancer patients and triple negative breast cancer patients. It is estimated that 490,000 Americans are diagnosed with cancers each year that are eligible for treatment with DNA damaging classes of drugs. This represents a one to two billion dollar market opportunity for the HRD test in the United States alone.

Under the terms of the agreement, Myriad will assess HRD status in patients who have been treated with PM1183 in PharmaMar's Phase II clinical study. Utilizing this information, Myriad and PharmaMar will hope to garner more information surrounding the role of HRD status in PM1183 response.

About PharmaMar

PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is Spain's first antitumour drug. Yondelis(R) is currently approved for soft tissue sarcoma (STS) in 42 countries outside the EEA, and for platinum-sensitive relapsed ovarian cancer (ROC) in 31 of those countries plus Brazil. Yondelis(R) is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA. Yondelis(R) is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin(R), PM01183, Zalypsis(R) and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program. For more information, please visit the Company's website: http://www.pharmamar.com

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

Continued here:
Myriad and PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test

Mar. 27, 2013 Researchers have identified genetic risk factors that may accelerate a teen's progression to becoming a lifelong heavy smoker.

The team of scientists from the U.S., the U.K. and New Zealand examined earlier studies by other research teams to develop a genetic risk profile for heavy smoking. Then they looked at their own long-term study of 1,000 New Zealanders from birth to age 38 to identify whether individuals at high genetic risk got hooked on cigarettes more quickly as teens and whether, as adults, they had a harder time quitting.

Study participants who had the high-risk genetic profile were found to be more likely to convert to daily smoking as teenagers and then progress more rapidly to heavy smoking (a pack a day or more). When assessed at age 38, the higher-risk individuals had smoked heavily for more years, had more often developed nicotine dependence and were more likely to have failed in attempts to quit smoking.

"Genetic risk accelerated the development of smoking behavior," said Daniel Belsky, a post-doctoral research fellow at Duke University's Center for the Study of Aging and Human Development and the Duke Institute for Genome Sciences & Policy. "Teens at a high genetic risk transitioned quickly from trying cigarettes to becoming regular, heavy smokers."

A person's genetic risk profile did not predict whether he or she would try cigarettes. But for those who did try cigarettes, having a high-risk genetic profile predicted increased likelihood of heavy smoking and nicotine dependence.

The findings appear March 27 in JAMA Psychiatry. They were supported by multiple grants from the U.S. National Institutes of Health, as well as the U.K. Medical Research Council and the New Zealand Health Research Council.

The Duke researchers developed a new "genetic risk score" for the study by examining prior genome-wide associations (GWAS) of adult smokers. These studies scanned the entire genomes of tens of thousands of smokers to identify variants that were more common in the heaviest smokers. The variants they identified were located in and around genes that affect how the brain responds to nicotine and how nicotine is metabolized, but it is not yet known how the specific variants affect gene function.

It makes sense that the genes on which the group based their risk score are involved in nicotine metabolism and sensitivity, said Jed Rose, a Duke nicotine addiction researcher who was not involved in this study. "Addictions are a learned behavior and it requires reinforcement through neural pathways."

In their first step, the researchers found the genetic risk score they developed was able to predict heavy smoking among individuals in two large databases created by other researchers.

Then they turned to their New Zealand sample of 880 individuals of European descent to see whether the genetic risk score predicted who initiated smoking, who progressed to heavy smoking, and who developed nicotine dependence and experienced relapse after quitting.

See the original post:
Genetics might determine which smokers get hooked